Invivyd (IVVD) EBT Margin (2024 - 2025)
Invivyd (IVVD) posted EBT Margin of 71.13% for Q4 2025, up 21.16% on a QoQ basis from 90.23% in Q3 2025, and up 6291.0% year-over-year from 1.11% in Q4 2024.
Invivyd (IVVD) EBT Margin (2024 - 2025) Analysis & Trends
Invivyd's EBT Margin history runs 2 years deep, the most recent figure standing at 71.13% for Q4 2025.
- Quarterly EBT Margin rose 6291.0% year-over-year to 71.13% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 105.99% (up 72245.0% YoY) and the FY2025 annual result came in at 576.11%, up 108373.0% from the prior year.
- EBT Margin was 71.13% for Q4 2025 at Invivyd, up from 90.23% in the prior quarter.
- Across five years, EBT Margin topped out at 71.13% in Q4 2025 and bottomed at 2194.43% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | -71.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -71.13% |
| Sep 30, 2025 | -90.23% |
| Jun 30, 2025 | -130.83% |
| Mar 31, 2025 | -151.47% |
| Dec 31, 2024 | -134.04% |
| Sep 30, 2024 | -674.69% |
| Jun 30, 2024 | -2,194.43% |